S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
F   9.23 (-0.97%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
F   9.23 (-0.97%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
F   9.23 (-0.97%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
F   9.23 (-0.97%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
DIS   146.38 (-0.93%)
Log in

NYSE:ZTS - Zoetis Stock Price, Forecast & News

$124.45
+0.12 (+0.10 %)
(As of 12/13/2019 04:00 PM ET)
Today's Range
$123.15
Now: $124.45
$124.62
50-Day Range
$116.17
MA: $121.34
$127.86
52-Week Range
$78.90
Now: $124.45
$130.20
Volume1.11 million shs
Average Volume2.09 million shs
Market Capitalization$59.28 billion
P/E Ratio39.76
Dividend Yield0.53%
Beta0.8
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP98978V10
Phone973-822-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.83 billion
Cash Flow$3.84 per share
Book Value$4.55 per share

Profitability

Net Income$1.43 billion

Miscellaneous

Employees10,000
Market Cap$59.28 billion
Next Earnings Date2/13/2020 (Estimated)
OptionableOptionable

Receive ZTS News and Ratings via Email

Sign-up to receive the latest news and ratings for ZTS and its competitors with MarketBeat's FREE daily newsletter.


Zoetis (NYSE:ZTS) Frequently Asked Questions

What is Zoetis' stock symbol?

Zoetis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZTS."

How often does Zoetis pay dividends? What is the dividend yield for Zoetis?

Zoetis declared a quarterly dividend on Friday, December 13th. Shareholders of record on Friday, January 17th will be given a dividend of $0.20 per share on Tuesday, March 3rd. This represents a $0.80 dividend on an annualized basis and a yield of 0.64%. The ex-dividend date is Thursday, January 16th. This is an increase from Zoetis's previous quarterly dividend of $0.16. View Zoetis' Dividend History.

How will Zoetis' stock buyback program work?

Zoetis announced that its Board of Directors has initiated a share repurchase plan on Wednesday, December 12th 2018, which allows the company to buyback $2,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to buy up to 4.7% of its shares through open market purchases. Shares buyback plans are generally an indication that the company's leadership believes its stock is undervalued.

How were Zoetis' earnings last quarter?

Zoetis Inc (NYSE:ZTS) posted its quarterly earnings data on Thursday, November, 7th. The company reported $0.94 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.88 by $0.06. The company earned $1.58 billion during the quarter, compared to the consensus estimate of $1.58 billion. Zoetis had a return on equity of 70.78% and a net margin of 23.76%. The business's quarterly revenue was up 7.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.83 earnings per share. View Zoetis' Earnings History.

When is Zoetis' next earnings date?

Zoetis is scheduled to release their next quarterly earnings announcement on Thursday, February 13th 2020. View Earnings Estimates for Zoetis.

What guidance has Zoetis issued on next quarter's earnings?

Zoetis updated its FY19 earnings guidance on Thursday, November, 7th. The company provided earnings per share guidance of $3.57-3.62 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.57. The company issued revenue guidance of $6.24 billion, compared to the consensus revenue estimate of prior $3.53-3.60.

What price target have analysts set for ZTS?

14 equities research analysts have issued 12-month target prices for Zoetis' stock. Their forecasts range from $86.00 to $145.00. On average, they anticipate Zoetis' stock price to reach $126.43 in the next twelve months. This suggests a possible upside of 1.6% from the stock's current price. View Analyst Price Targets for Zoetis.

What is the consensus analysts' recommendation for Zoetis?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last year. There are currently 6 hold ratings, 7 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zoetis.

Has Zoetis been receiving favorable news coverage?

Media stories about ZTS stock have trended somewhat positive this week, InfoTrie reports. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Zoetis earned a media sentiment score of 1.7 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Zoetis.

Are investors shorting Zoetis?

Zoetis saw a increase in short interest during the month of November. As of November 29th, there was short interest totalling 4,980,000 shares, an increase of 43.1% from the November 14th total of 3,480,000 shares. Based on an average trading volume of 2,180,000 shares, the days-to-cover ratio is currently 2.3 days. Approximately 1.1% of the shares of the company are short sold. View Zoetis' Current Options Chain.

Who are some of Zoetis' key competitors?

What other stocks do shareholders of Zoetis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zoetis investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Transocean (RIG), Micron Technology (MU) and Gran Tierra Energy (GTE).

Who are Zoetis' key executives?

Zoetis' management team includes the folowing people:
  • Mr. Juan Ramón Alaix, CEO & Director (Age 68)
  • Mr. Glenn C. David, Exec. VP & CFO (Age 47)
  • Dr. Catherine A. Knupp, Exec. VP and Pres of R&D (Age 58)
  • Mr. Clinton A. Lewis Jr., EVP and Grp Pres of Intl. Ops., Comm. Devp., Glbl Genetics, Aquatic Health & Human Medical Digs (Age 52)
  • Ms. Kristin C. Peck, Exec. VP and Group Pres of U.S. Operations, Bus. Devel. & Strategy (Age 48)

Who are Zoetis' major shareholders?

Zoetis' stock is owned by a number of of retail and institutional investors. Top institutional investors include State Street Corp (4.12%), Massachusetts Financial Services Co. MA (1.58%), Cantillon Capital Management LLC (0.77%), California Public Employees Retirement System (0.50%), CIBC Private Wealth Group LLC (0.49%) and Sumitomo Mitsui Trust Holdings Inc. (0.41%). Company insiders that own Zoetis stock include Andrew Fenton, Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Heidi C Chen, Juan Ramon Alaix, Khosla Sanjay, Kristin C Peck, Roman Trawicki, Roxanne Lagano and Willie M Reed. View Institutional Ownership Trends for Zoetis.

Which major investors are selling Zoetis stock?

ZTS stock was sold by a variety of institutional investors in the last quarter, including Voya Investment Management LLC, Ardevora Asset Management LLP, State of New Jersey Common Pension Fund D, Artemis Investment Management LLP, Pictet Asset Management Ltd., Massachusetts Financial Services Co. MA, State Street Corp and AMF Pensionsforsakring AB. Company insiders that have sold Zoetis company stock in the last year include Andrew Fenton, Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Heidi C Chen, Juan Ramon Alaix, Kristin C Peck, Roman Trawicki, Roxanne Lagano and Willie M Reed. View Insider Buying and Selling for Zoetis.

Which major investors are buying Zoetis stock?

ZTS stock was bought by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, CIBC Private Wealth Group LLC, Nomura Holdings Inc., Sumitomo Mitsui Trust Holdings Inc., State of Tennessee Treasury Department, Railway Pension Investments Ltd, Voloridge Investment Management LLC and Jag Capital Management LLC. View Insider Buying and Selling for Zoetis.

How do I buy shares of Zoetis?

Shares of ZTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Zoetis' stock price today?

One share of ZTS stock can currently be purchased for approximately $124.45.

How big of a company is Zoetis?

Zoetis has a market capitalization of $59.28 billion and generates $5.83 billion in revenue each year. The company earns $1.43 billion in net income (profit) each year or $3.13 on an earnings per share basis. Zoetis employs 10,000 workers across the globe.View Additional Information About Zoetis.

What is Zoetis' official website?

The official website for Zoetis is http://www.zoetis.com/.

How can I contact Zoetis?

Zoetis' mailing address is 10 Sylvan Way, Parsippany NJ, 07054. The company can be reached via phone at 973-822-7000 or via email at [email protected]


MarketBeat Community Rating for Zoetis (NYSE ZTS)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  744 (Vote Outperform)
Underperform Votes:  439 (Vote Underperform)
Total Votes:  1,183
MarketBeat's community ratings are surveys of what our community members think about Zoetis and other stocks. Vote "Outperform" if you believe ZTS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZTS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/13/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel